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Experimental animals and diets.  6-week old, male B6.V-Lepob/OlaHsd (ob/ob) mice were obtained through Harlan 
(Indianapolis, IN) and housed 4/cage at 22oC ± 0.5oC on a 12-hour light/dark cycle.  Mice were maintained on 
isocaloric, modified AIN-93G diets (Bio-Serv, Frenchtown, NJ) containing 6.5% fat.  Diets contained either 6.5% 
soybean oil (CON) or 5% soybean oil and 1.5% CLA mixed triglycerides (CLA).  CLA mixed triglycerides (Tonalin TG 
80, Cognis Corp., Cincinnati, OH) were ~80% CLA composed of 39.2% c9t11- and 38.5% t10c12-CLA isomers.
Experimental design.  In a 2x2 factorial design, mice were fed either the CON or CLA diet and received daily 
injections intraperitoneally of either 1 mg/kg BW recombinant mouse leptin (R&D Systems, Minneapolis, MN) (CON + 
or CLA +) or a similar volume of the vehicle PBS (CON - or CLA -) for 4 weeks (n=8 mice per diet +/- leptin group).  
Mice were injected daily 2 hours before the dark cycle.
Fasting glucose and insulin tolerance test.  Glucose levels were measured after a 12 hr fast at baseline and at 2 
and 4 weeks of experimental treatments via tail blood using a One Touch Basic glucometer (Lifescan, Milpitas, CA).  
An insulin tolerance test was conducted after 4 weeks of  dietary and leptin intervention after an overnight (12 hr) fast.  
Mice were injected intraperitoneally with 1.5 U/kg BW insulin (Humulin® R, Eli Lilly and Co., Indianapolis, IN).  Tail 
vein blood was used to measure glucose prior to injection (time 0) and at 15, 30, 45, 60, 90, and 120 minutes 
following the injection.  Area under the curve (AUC) was calculated as the net area contained between individual 
baselines (set by the glucose value at time 0) and curves using the trapezoidal rule4.
Insulin and Adiponectin.  Fasted serum levels of insulin and adiponectin were determined by ELISA (Linco
Research, Inc., St. Charles, MO) according to manufacturer’s directions.
Analysis of triglycerides and free fatty acids. Serum free fatty acids were determined using a colorimetric kit 
(NEFA C, Wako Chemicals, Richmond, VA).  Lipids were extracted from tissues using the Folch3 method.  Extracts 
were solublized in 3:1:1 (v/v/v) tert-butanol, methanol, Trition X-100.  Serum and tissue lipid extracts were analyzed 
for triglycerides by colorimetric enzymatic hydrolysis (Triglyceride, GPO-Trinder, reagents, Sigma, St. Louis, MO). 
RT-PCR. RNA was isolated from tissue with Trizol (Invitrogen, Carlsbad, CA) and reverse transcribed with High 
Capacity cDNA Archive Kit (ABI, Foster City, CA) according to directions. cDNA was amplified by real-time PCR in a 
total reaction volume of 25 µl with TaqMan Gene Expression Assays (ABI) using pre-designed and validated primers 
(FAM probes) from ABI under universal cycling conditions defined by ABI.  Target gene expression was normalized to 
the endogenous control 18s (VIC probe) amplified in the same reaction.
Statistical analysis. Data are expressed as least square mean (LSM) ± standard error (SE).  Interactions of diet 
(CON or CLA) and treatment (leptin or vehicle) were analyzed by two-way ANOVA using the MIXED procedure of 
Statistical Analysis System (SAS v9.1; Cary, NC).  Fasting glucoses and glucose curves were analyzed as repeated 
measures. Differences of P<0.05 were considered significant. 
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Materials & Methods
Determine the individual and interactive effects of CLA and leptin on 
insulin resistance and lipid metabolism in ob/ob mice.
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Conjugated linoleic acid (CLA) reduces adipose mass and enhances insulin sensitivity in several 
animal models.  Conversely, in some rodent models, CLA induces lipodystrophy, insulin 
resistance, and reduces adipokines.  Leptin is an insulin sensitizing adipokine that may work by 
suppressing steatosis in liver and muscle, a condition that may contribute to insulin resistance.  
Therefore, we hypothesize that leptin prevents CLA-induced insulin resistance in obese mice by 
attenuating steatosis.  In a 2x2 factorial design, 6-week old, male ob/ob mice were fed either a 
control diet or a diet supplemented with 1.5% mixed isomer CLA and received daily 
intraperitoneal injections of either PBS or 1.0 mg/kg leptin for 4 weeks.  CLA and leptin alone or 
in combination decreased weight gain, which was reflected by a reduction of epididymal fat mass.  
At 2 and 4 weeks of feeding, leptin significantly attenuated CLA-induced increased fasting 
glucose, and at 4 weeks, leptin prevented CLA-induced insulin resistance.  Although CLA alone 
significantly increased fasting insulin, leptin reduced fasting insulin levels in both diet groups.  
CLA significantly reduced serum adiponectin, regardless of leptin treatment.  Liver and muscle 
triglycerides (TG) were not altered by CLA alone; however, leptin reduced liver and muscle TG in 
both diet groups.  Fatty acid synthase mRNA, a marker of lipid synthesis was decreased by 
leptin, regardless of diet, but CPT-1, a marker of lipid oxidation, was not changed.  These data 
suggest that restoration of insulin sensitivity by leptin may partially be attributed to the reduction 
of hepatic steatosis and by compensating for the reduction of adiponectin.
Abstract
Introduction
B6.V-Lepob/OlaHsd (ob/ob) mice
• Leptin (lep-/lep-) mutation
• Obese
• Hyperinsulinemic
• Insulin resistant
• Hyperlipemic
• Hepatic steatosis
• Adipocyte hyperplasia
Table 1.  Effects of CLA and Leptin on Body Weights and Tissue Sizes
* Values represent LSM ± SE with significant differences (p<0.05) denoted by different superscripts within each row
In ob/ob mice:
•CLA worsened insulin resistance; leptin prevented CLA-induced insulin resistance, 
•CLA increased fasting glucose and insulin, and serum triglycerides; leptin prevented these increases
•CLA decreased serum adiponectin concentration; administration of leptin had no effect on adiponectin
•CLA did not increase hepatic steatosis compared to control diet alone
•Leptin decreased hepatic and muscle triglyceride concentrations; leptin decreased hepatic lipid synthesis, but did not affect 
hepatic lipid oxidation
These results show that despite ob/ob mice being overtly obese, CLA significantly reduces adipose mass and 
adiponectin and significantly worsens insulin resistance.  Administration of leptin to CLA-fed mice does not alter 
adipose mass or adiponectin, but prevents insulin resistance.  The effects of leptin on insulin resistance in CLA-
fed mice may be modulated through the reduction of hepatic steatosis and by compensating for the reduction of 
adiponectin.  
Summary
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Conjugated Linoleic Acid (CLA) (rev. in 1)
• Reduces adipose mass in a variety of species
• Controversial, species-specific effects on metabolism and insulin resistance
•In obese rats:
•Improves glucose and insulin tolerance
•Maintains or increases adipocytokines
•Loss of adipose perhaps not as severe as in mice
•In mice:
•Reduces adipocytokines
•Induces lipdystrophy and liver steatosis
•Induces insulin resistance 
• Modulation of insulin sensitivity 
possibly dependent on maintenance 
of certain level of adipose and therefore adipocytokines
COOH
COOH c9t11-CLA
t10c12-CLA
Leptin (rev. in 2)
• 16 kDa hormone produced by adipocytes
• Circulates at levels proportional to adipose tissue
• Appetite suppressant
•Metabolic effects largely independent of food intake
• Regulates energy homeostasis
• Leptin deficiency results in accumulation of lipid in tissues, such as adipose and liver
•Leads to disorders such as obesity, insulin resistance, and non-alcoholic fatty liver 
disease (NAFLD)
Fig. 1. Leptin prevents CLA-induced insulin resistance. Mice were fed either control (CON) or CLA-
supplemented (CLA) diets and received either leptin (+) or vehicle (-) by IP injection daily.  After 4 weeks, mice 
received 1.5 U/kg insulin by IP injection after an overnight fast (12 hr).  Blood glucose was measured at intervals 
indicated over 2 hrs.  A. Glucose response to insulin tolerance test over time.  Values represent LSM of n=8 mice.  
Statistical differences at each time point were omitted for clarity.  B. Net area contained within curve of insulin 
tolerance test.  Area was calculated as the net area contained between individual baselines (set by the glucose 
value at time 0) and curves using the trapezoidal rule. Values represent LSM ± SE with significant differences 
(p<0.05) denoted by different superscripts.
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Table 2.  Effects of CLA and Leptin on Fasting Insulin, Glucose, NEFA, and Serum Triglyceride Levels
101.25 ± 8.88b69.075 ± 8.88a112.09 ± 8.88b81.4 ± 8.88aGastrocnemius muscle (g)
1.363 ± 0.136a1.713 ± 0.136a2.163 ± 0.136b2.963 ± 0.136cEpididymal adipose (g)
1.563 ± 0.173a3.175 ± 0.173b1.288 ± 0.173a2.763 ± 0.173bLiver (g)
28.41 ± 0.97a28.98 ± 0.97a34.79 ± 0.97b42.20 ± 0.97cFinal body weight (g)
CLA +CLA -CON +CON -
* Values represent LSM ± SE with significant differences (p<0.05) from baseline denoted by #; baseline values among diet/treatment groups were not significantly different.
** Values represent LSM ± SE with significant differences (p<0.05) denoted by different superscripts within each row.
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Tissue Triglycerides
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Fig. 3. Leptin decreases liver and muscle lipid accumulation. Mice were fed 
either control (CON) or CLA-supplemented (CLA) diets and received either leptin (+) 
or vehicle (-) by IP injection daily.  After 4 weeks, fasted mice were sacrificed.  
Triglycerides were measured from lipid extracts of tissues  A. Triglyceride 
concentration (mg TG/g tissue) of liver.  Values represent LSM ± SE of n=8 mice 
with significant differences (p<0.05) denoted by different superscripts. B.
Triglyceride concentration (mg TG/g tissue) of muscle. Values represent LSM ± SE 
of n=8 mice with significant differences (p<0.05) denoted by different superscripts.
A B
103.23 ± 14.42ab131.45 ± 14.42b122.94 ± 12.49ab88.13 ± 14.42aSerum triglyceride (mg/dl)**
0.8250 ± 0.08751.0263 ± 0.08750.8325 ± 0.08750.9029 ± 0.094Serum NEFA (mEq/L)**
1452.5 ± 486.3a5455.8 ± 519.9c660.2 ± 486.3a3066.6 ± 519.9bFasting insulin (pg/ml)**
98.38 ± 10.38153.63 ± 10.38*89.50 ± 10.38122.87 ± 10.384 weeks
102.50  ± 10.38161.59 ± 12.10*106.25  ± 10.38130.25 ± 10.382 weeks
107.38 ± 10.38101.25 ± 10.38117.00 ± 10.38115.12 ± 10.38baseline
Fasting glucose (mg/dl)*
CLA +CLA -CON +CON -
Adiponectin
Fig. 2. CLA decreases serum 
adiponectin. Mice were fed either control 
(CON) or CLA-supplemented (CLA) diets 
and received either leptin (+) or vehicle (-) 
by IP injection daily.  After 4 weeks, serum 
adiponectin was measured by an ELISA 
from fasted mice. Values represent LSM ± 
SE of n=8 mice with significant differences 
(p<0.05) denoted by different superscripts.
Objective
Fig. 4. Leptin decreases fatty acid synthase
(FAS), but does not change carnitine
palmitoyl transferase-1 (CPT-1) hepatic 
mRNA expression. Mice were fed either control 
(CON) or CLA-supplemented (CLA) diets and 
received either leptin (+) or vehicle (-) by IP 
injection daily.  After 4 weeks, A. FAS and B.
CPT-1 mRNA were measured from livers of 
fasted mice by RT-PCR. Values represent LSM ± 
SE of n=8 mice with significant differences 
(p<0.05) denoted by different superscripts.CON - CON + CLA - CLA +
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Hepatic Markers of Lipid Synthesis and Oxidation
Insulin Tolerance
